Beijing Biostar Pharmaceuticals Co., Ltd. (HKG:2563)
4.500
0.00 (0.00%)
May 7, 2026, 3:43 PM HKT
HKG:2563 Revenue
In the year 2025, Beijing Biostar Pharmaceuticals had annual revenue of 33.36M CNY, down -53.57%. Beijing Biostar Pharmaceuticals had revenue of 18.58M in the half year ending December 31, 2025.
Revenue
33.36M CNY
Revenue Growth
-53.57%
P/S Ratio
44.19
Revenue / Employee
248.99K CNY
Employees
134
Market Cap
1.64B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 33.36M | -38.50M | -53.57% |
| Dec 31, 2024 | 71.87M | 5.23M | 7.85% |
| Dec 31, 2023 | 66.64M | 33.82M | 103.03% |
| Dec 31, 2022 | 32.82M | -38.24M | -53.82% |
| Dec 31, 2021 | 71.06M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Frontage Holdings | 2.00B |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.45B |
| Mabpharm | 718.98M |
| Cutia Therapeutics | 374.07M |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 171.70M |
| CANbridge Pharmaceuticals | 55.62M |
| Shanghai Bio-heart Biological Technology | 50.00M |
| Kintor Pharmaceutical | 36.37M |